When: Price falls below $184.52 (recent swing low)

Then: Exit any new position; ATR of 4.73 makes $189 stop too loose

HOLD with disciplined entry triggers: buy on confirmed close above 200 with 25%+ volume expansion OR on pullback to 175-180; maintain 184.52 stop

• PM trading at 21.2x forward P/E with consensus EPS growth of only 5-7%, implying market pricing in roughly double the expected growth
• 3.03% dividend yield is out-yielded by 4.7% 10-year Treasuries, making the yield-arbitrage argument actually argue against buying PM
• Stock up only 0.2% since last earnings despite 11 FDA Marketing Granted Orders for ZYN ULTRA, suggesting limited market rerating
• Upper Bollinger Band at 194.42 with fresh MACD cross on weak 4.57M volume and negative 30-day performance of -3.12% is momentum exhaustion, not confirmation
• ATR compressing at 4.73 is direction-agnostic and can coil for downward movement
• Altria deal is an 18+ month 2027 story with no near-term revenue impact
• 17.3B Swedish Match goodwill represents material write-down risk; 2024 already saw 2.3B extraordinary charge and doubled interest expense of 1.59B vs 768M
• Negative book value limits capacity to absorb goodwill write-downs and creates credit rating sensitivity
• Retail corroboration absent, with sentiment confidence capped at Medium
• Rerating is largely done: 5-year returns of 132.9% and YTD of 17.42% mean upside is 8-13% while downside is 12-18% from near 52-week highs

→ vs aggressive: PEG of 2.45 is not justified for a 5-7% grower; fair P/E is 12-17x, not 21.2x current valuation

→ vs aggressive: MACD cross at upper Bollinger is momentum exhaustion, not a buy signal; the textbook definition of a setup that historically pulls back

→ vs aggressive: 11 FDA approvals haven't moved the stock (up only 0.2% since earnings); the market is not rerating on ZYN

→ vs aggressive: Calling negative book value 'just a feature' is a half-truth; it creates goodwill write-down vulnerability and credit sensitivity

→ vs aggressive: 87% probability of zero cuts being bullish for defensives ignores that PM trades at a growth multiple, not defensive

→ vs aggressive: Tightening breakout trigger to 197 from 200 is trigger-chasing in a mean-reverting environment

→ vs aggressive: The 'missing the rerating' concern is overstated given 132.9% 5-year gains; now chasing the last 8-13% with 12-18% downside risk

→ vs aggressive: Regulatory tail risk on nicotine pouches (flavor bans, state restrictions, FDA posture shifts) completely ignored

HOLD - don't chase at 194.10; use tiered entry: 188-190 confirmed pullback for 25% size add, 196.50 close with volume confirmation for breakout entry, 200 with 25% volume for full conviction add; stop at 184.52; consider put protection or pair-trade against Altria to hedge regulatory tail risk

• Current price 194.10 is at upper Bollinger Band on light volume with no confirmed breakout - don't chase
• Tiered pullback entry: 188-190 with technical confirmation (higher low on daily, RSI holds above 55, MACD histogram stays positive) for 25% size add
• Full size add only at 175-180 into 200 SMA at 171.29
• Breakout trigger: close at 196.50 with volume at least 20% above 5-day average
• Alternative breakout: 200 with 25% volume expansion for full conviction add
• Stop at 184.52 - recent swing low that defines the bullish setup; 189 stop too loose given ATR of 4.73
• Risk per unit should not exceed 2% of portfolio NAV
• Consider put protection at 175 strike expiring in 3-6 months, or pair-trade against Altria to hedge regulatory binary tail risk
• FDA granted 11 Marketing Orders for ZYN ULTRA (all 9mg variants plus one 11mg variant) - regulatory de-risking partially complete
• Swedish Match goodwill impairment risk is real but bounded - 2024 extraordinary charge was 2.3 billion and stock is up substantially since
• Total return case: dividend plus 5-7% EPS growth plus multiple stability = 8-10% total return, not a pure income play
• Position sizing discipline critical - single-asset bet on smoke-free transition; 12-18% downside if binary risk materializes

→ vs aggressive: 190-191 is a midpoint between 50 SMA at 186.51 and upper Bollinger at 194.42 with no tested support - buying a dip that hasn't been technically confirmed is hope dressed as a level, not asymmetry in our favor

→ vs aggressive: Tightening breakout trigger to 197 is looser than conservative's 200, not better - one close at 197 on average volume gets faded; the point was to require decisive close with volume expansion to filter mean-reversion noise

→ vs aggressive: Completely waved off regulatory tail risk when FDA's 11 Marketing Granted Orders for ZYN ULTRA represents constructive regulatory engagement, not hostility

→ vs conservative: PEG math (2.45 on 5-7% growth = 12-17x fair P/E) uses a static growth assumption that may be too low given PM's smoke-free mix is shifting from majority to two-thirds of revenue

→ vs conservative: Yield out-yielded by Treasuries argument is overweighted - 3.03% yield supplements an appreciation thesis, not the reason to own the stock; total return case is 8-10%

→ vs conservative: Breakout trigger at 200 is too strict given intraday high already hit 196.66 - risking watching stock run from 195-200 with no entry only to see it reverse at 200

→ vs conservative: Binary regulatory tail risk is real but partially de-risked by recent FDA action - overweighting it by ignoring regulatory de-risking already happened

→ vs conservative: Position sizing discipline critical - neither analyst adequately addressed sizing the position so either outcome (missing rerating or regulatory reversal) is survivable